Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genelux Corp (GNLX)

Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,287
  • Shares Outstanding, K 38,052
  • Annual Sales, $ 10 K
  • Annual Income, $ -29,870 K
  • EBIT $ -34 M
  • EBITDA $ -34 M
  • 60-Month Beta 0.07
  • Price/Sales 22,070.16
  • Price/Cash Flow N/A
  • Price/Book 9.52

Options Overview Details

View History
  • Implied Volatility 789.73% (+53.69%)
  • Historical Volatility 130.76%
  • IV Percentile 94%
  • IV Rank 74.49%
  • IV High 1,040.14% on 04/04/25
  • IV Low 58.49% on 09/08/25
  • Expected Move (DTE 10) 0.30 (6.81%)
  • Put/Call Vol Ratio 0.91
  • Today's Volume 21
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,102
  • Open Int (30-Day) 959
  • Expected Range 4.07 to 4.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.23
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.37 unch
on 12/08/25
6.26 -30.19%
on 11/12/25
-1.05 (-19.37%)
since 11/07/25
3-Month
3.48 +25.57%
on 09/09/25
8.53 -48.77%
on 11/05/25
+0.81 (+22.75%)
since 09/08/25
52-Week
1.99 +119.87%
on 04/09/25
8.53 -48.77%
on 11/05/25
+1.66 (+61.25%)
since 12/06/24

Most Recent Stories

More News
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference

WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 4.37 (-5.82%)
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026...

GNLX : 4.37 (-5.82%)
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference

WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO...

GNLX : 4.37 (-5.82%)
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter...

GNLX : 4.37 (-5.82%)
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

GNLX : 4.37 (-5.82%)
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

GNLX : 4.37 (-5.82%)
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

GNLX : 4.37 (-5.82%)
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GNLX : 4.37 (-5.82%)
Employment Reports to Roll Out Next Friday in Both Countries

Employment Reports to Roll Out Next Friday in Both Countries U.S. Monday Featured Earnings ...

PVH : 74.84 (-4.65%)
LIEN : 10.69 (+0.09%)
SPWH : 1.6900 (+2.42%)
CAG : 17.14 (+0.18%)
PRGS : 43.88 (+0.78%)
PENG : 22.11 (+2.46%)
LW : 59.53 (-0.28%)
UNF : 179.65 (-0.20%)
BYRN : 18.99 (-3.46%)
LEVI : 21.64 (unch)
AYI : 373.41 (+0.31%)
NCNO : 24.58 (+5.09%)
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

GNLX : 4.37 (-5.82%)

Business Summary

Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary,...

See More

Key Turning Points

3rd Resistance Point 5.45
2nd Resistance Point 5.24
1st Resistance Point 4.80
Last Price 4.37
1st Support Level 4.15
2nd Support Level 3.94
3rd Support Level 3.50

See More

52-Week High 8.53
Fibonacci 61.8% 6.03
Fibonacci 50% 5.26
Fibonacci 38.2% 4.49
Last Price 4.37
52-Week Low 1.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar